Sorbent Therapeutics Secures $21,800,000 Series B Funding
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2c8bb69b-2b90-4352-8095-96a52399a5ee&Preview=1
Date 9/13/2010
Company Name Sorbent Therapeutics
Mailing Address 750 East Bunker Court Vernon Hills, IL 60061
Company Description Sorbent Therapeutics is a biopharmaceutical company focused on the development of adaptable non-absorbed polymeric drugs to satisfy unmet clinical needs in large markets such as End Stage Renal Disease (ESRD), Congestive Heart Failure (CHF), Chronic Kidney Disease (CKD), and Hypertension.
Proceeds Purposes Sorbent will use the capital to advance the clinical development of its lead drug candidate CLP-1001 for patients with sodium and fluid overload or risk for hyperkalemia in renal and cardiovascular diseases, such as End Stage Renal Disease and Congestive Heart Failure.